Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus

Stopped early · Phase 2

Conditions studied: Diabetes Mellitus

In brief

This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).

Key facts

Study ID

NCT00143247

Run by

Pfizer

People needed

173

Starts

2003-03-01

Expected to finish

2008-01-01

Last updated by the study team

2010-04-15

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects with Type 1 or Type 2 Diabetes Mellitus who participated in previous Phase 2 extension protocols

You may not qualify if…

• Smoking
• Pregnancy

Where it is running

• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Albuquerque, New Mexico, United States
• Pfizer Investigational Site — Durham, North Carolina, United States
• Pfizer Investigational Site — Winston-Salem, North Carolina, United States
• Pfizer Investigational Site — Austin, Texas, United States
• Pfizer Investigational Site — Austin, Texas, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — Dallas, Texas, United States
• Pfizer Investigational Site — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.